Learning from nemolizumab: A promising therapy for prurigo nodularis - 05/06/24
Doi : 10.1016/j.jaci.2024.02.016
Brian S. Kim, MD, MTR a, b, c, d, e, ⁎ 
a Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
b Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai, New York, NY
c Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY
d Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY
e Allen Discovery Center for Neuroimmune Interactions, Icahn School of Medicine at Mount Sinai, New York, NY
∗Corresponding author: Brian S. Kim, MD, MTR, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave, New York, NY 10029.Icahn School of Medicine at Mount Sinai1425 Madison AveNew YorkNY10029
Key words : Atopic dermatitis, dupilumab, oncostatin M, nemolizumab, prurigo nodularis, IL-4Rα, IL-31
El texto completo de este artículo está disponible en PDF.
© 2024
American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 153 - N° 6
P. 1548-1549 - juin 2024 Regresar al número
Artículo precedente
- Should “primary immune disorder” replace “inborn error of immunity”? Names matter, but there is room for both
- Stuart E. Turvey, Catherine M. Biggs, Elliot L. James, Kyla J. Hildebrand
- On mentoring and being mentored—a lifetime journey and legacy
- Wanda Phipatanakul
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?